P53 deletion may drive the clinical evolution and treatment response in multiple myeloma

• Published in: European journal of haematology Vol. 84; no. 4; pp. 359 - 361
• Main Authors: López‐Anglada, Lucía, Gutiérrez, Norma C., García, Juan L., Mateos, María V., Flores, Teresa, San Miguel, Jesús F.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.04.2010
• Subjects: Chromosomes, Human, Pair 14 - genetics; Chromosomes, Human, Pair 4 - genetics; cytogenetics; Female; Gene Deletion; Humans; Middle Aged; Multiple Myeloma - genetics; Multiple Myeloma - therapy; myeloma; Neoplasms, Second Primary - genetics; Neoplasms, Second Primary - therapy; P53; plasmacytoma; Plasmacytoma - genetics; Plasmacytoma - therapy; Retinoblastoma Protein - genetics; Translocation, Genetic - genetics; Tumor Suppressor Protein p53 - genetics
• ISSN: 0902-4441; 1600-0609
• DOI: 10.1111/j.1600-0609.2009.01399.x

We report a patient with multiple myeloma presenting with a paraspinal plasmacytoma with a marked dissociation between the response obtained in bone marrow (BM) infiltration and that achieved in soft tissue masses. While a complete remission was reached and maintained in BM, extramedullary plasmacytomas were refractory to every line of treatment. Genetic analysis identified the presence of t(4;14) and RB deletion in myeloma cells of both origins. However, a P53 deletion was only detected in plasma cells from extramedullary plasmacytomas. This finding suggests that P53 deletion has a role in the lack of treatment response of extramedullary plasmacytomas.